JP4324379B2 - ルブラウイルス（ｒｕｂｕｌａｖｉｒｕｓ）属に属するニューロビルレントウイルス（ｎｅｕｒｏｖｉｒｕｌｅｎｔ）（クリプトウイルス（ｃｒｙｐｔｏｖｉｒｕｓ））とその使用 - Google Patents

ルブラウイルス（ｒｕｂｕｌａｖｉｒｕｓ）属に属するニューロビルレントウイルス（ｎｅｕｒｏｖｉｒｕｌｅｎｔ）（クリプトウイルス（ｃｒｙｐｔｏｖｉｒｕｓ））とその使用 Download PDF

Info

Publication number
JP4324379B2
JP4324379B2 JP2002576654A JP2002576654A JP4324379B2 JP 4324379 B2 JP4324379 B2 JP 4324379B2 JP 2002576654 A JP2002576654 A JP 2002576654A JP 2002576654 A JP2002576654 A JP 2002576654A JP 4324379 B2 JP4324379 B2 JP 4324379B2
Authority
JP
Japan
Prior art keywords
cryptovirus
seq
leu
antibody
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002576654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005503766A (ja
JP2005503766A5 (https=
Inventor
スティーヴン ジェイ ロビンス
Original Assignee
クリプティック アフリクションズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリプティック アフリクションズ リミテッド ライアビリティ カンパニー filed Critical クリプティック アフリクションズ リミテッド ライアビリティ カンパニー
Publication of JP2005503766A publication Critical patent/JP2005503766A/ja
Publication of JP2005503766A5 publication Critical patent/JP2005503766A5/ja
Application granted granted Critical
Publication of JP4324379B2 publication Critical patent/JP4324379B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
JP2002576654A 2001-02-07 2002-02-07 ルブラウイルス（ｒｕｂｕｌａｖｉｒｕｓ）属に属するニューロビルレントウイルス（ｎｅｕｒｏｖｉｒｕｌｅｎｔ）（クリプトウイルス（ｃｒｙｐｔｏｖｉｒｕｓ））とその使用 Expired - Fee Related JP4324379B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26725301P 2001-02-07 2001-02-07
PCT/US2002/004117 WO2002077211A2 (en) 2001-02-07 2002-02-07 A virus (cryptovirus) within the rubulavirus genus and uses therefor

Publications (3)

Publication Number Publication Date
JP2005503766A JP2005503766A (ja) 2005-02-10
JP2005503766A5 JP2005503766A5 (https=) 2005-12-22
JP4324379B2 true JP4324379B2 (ja) 2009-09-02

Family

ID=23017976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002576654A Expired - Fee Related JP4324379B2 (ja) 2001-02-07 2002-02-07 ルブラウイルス（ｒｕｂｕｌａｖｉｒｕｓ）属に属するニューロビルレントウイルス（ｎｅｕｒｏｖｉｒｕｌｅｎｔ）（クリプトウイルス（ｃｒｙｐｔｏｖｉｒｕｓ））とその使用

Country Status (6)

Country Link
EP (1) EP1373477B1 (https=)
JP (1) JP4324379B2 (https=)
AT (1) ATE517179T1 (https=)
AU (2) AU2002306472C1 (https=)
CA (1) CA2436208C (https=)
WO (1) WO2002077211A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
FR2938840B1 (fr) * 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
FR2938841B1 (fr) 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
WO2011150320A2 (en) * 2010-05-27 2011-12-01 University Of Georgia Research Foundation, Inc. Activators of innate immunity
CN113481185B (zh) * 2021-08-05 2022-12-02 云南师范大学 一种耐盐β-半乳糖苷酶GalNC2-13及其制备方法和应用
WO2025076466A2 (en) * 2023-10-06 2025-04-10 Cyanvac Llc Piv5-based vaccines with modified antigen: methods of making and using the same

Also Published As

Publication number Publication date
AU2002306472B2 (en) 2008-03-06
JP2005503766A (ja) 2005-02-10
WO2002077211A8 (en) 2002-11-21
ATE517179T1 (de) 2011-08-15
CA2436208C (en) 2014-04-15
CA2436208A1 (en) 2002-10-03
WO2002077211A3 (en) 2003-10-16
AU2002306472C1 (en) 2008-10-30
AU2008202524A1 (en) 2008-06-26
EP1373477A2 (en) 2004-01-02
WO2002077211A2 (en) 2002-10-03
EP1373477B1 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
Mahapatra et al. Matrix protein and glycoproteins F and H of Peste-des-petits-ruminants virus function better as a homologous complex
Schmaljohn et al. Isolation and initial characterization of a newfound hantavirus from California
Fraser et al. Measles virus and its biology
Oberste et al. Association of Venezuelan equine encephalitis virus subtype IE with two equine epizootics in Mexico.
ES2344150T3 (es) Procedimientos y reactivos para diagnosticar la infeccion por hantavirus.
JPH05506773A (ja) 新規のｈｃｖ分離株
US20130230529A1 (en) Novel paramyxovirus and uses thereof
AU2008202524A1 (en) Neurovirulent virus (cryptovirus) within the rebulavirus genus and uses therefor
US10329584B2 (en) Modified Sendai virus vaccine and imaging vector
Collen et al. Single amino acid differences are sufficient for CD4+ T-cell recognition of a heterologous virus by cattle persistently infected with bovine viral diarrhea virus
US20070150972A1 (en) Method for detecting Nipah virus and method for providing immunoprotection against Henipa viruses
US6593080B1 (en) Diagnosis, prevention and treatment of calicivirus infection in humans
Oldstone et al. Disease accompanying in utero viral infection: the role of maternal antibody in tissue injury after transplacental infection with lymphocytic choriomeningitis virus
Johnson et al. In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation
AU2002306472A1 (en) Neurovirulent Virus (Cryptovirus) Within the Rubulavirus Genus and Uses Therefor
CN109476708A (zh) 针对致关节炎甲病毒的疫苗
AKASU Outbreak of Aseptic Meningitis due to ECHO-9 in Northern Kyushu Island inthe Summer of 1997
US20020018784A1 (en) Vaccine against mumps containing a jeryl-lynn virus strain
PT1780216E (pt) Coronavírus canino pantrópico
Fang et al. Construction and characterization of an infectious cDNA clone of encephalomyocarditis virus from pigs in China
Talekar et al. Measles: The Disease That Refuses to Be Vanquished
Kumar Attenuation and characterization of an indian isolate of canine distemper virus as a vaccine candidate
Harter Sheep progressive pneumonia viruses
Yadav Development and Evaluation of Stable Vero Cell Line Constitutively Expressing Signaling Lymphocyte Activation Molecule (SLAM) and Nectin-4 Receptors for Replication Efficacy of Peste-des-petits-ruminants and Canine distemper viruses
HK40096253A (zh) 戊型肝炎病毒样颗粒及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080526

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090511

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090608

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120612

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130612

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees